MedTrace Logo

A Study of Modified mRNA Vaccines in Healthy Adults

NCT05397223 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 308

Last updated 2026-03-12

No results posted yet for this study

Summary

The main goal of this study is to evaluate the safety, reactogenicity, and immunogenicity of study vaccines.

Conditions

Interventions

BIOLOGICAL

mRNA-1273

Sterile liquid for injection

BIOLOGICAL

mRNA-1010

Sterile liquid for injection

BIOLOGICAL

mRNA-1345

Sterile liquid for injection

BIOLOGICAL

FLUAD®

adjuvanted (MF59), inactivated, quadrivalent seasonal influenza vaccine

BIOLOGICAL

mRNA-1647

Sterile lyophilized product

Sponsors & Collaborators

  • ModernaTX, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-05-24
Primary Completion
2026-02-27
Completion
2026-02-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05397223 on ClinicalTrials.gov